Alan Yagoda

8.1k total citations · 4 hit papers
104 papers, 6.1k citations indexed

About

Alan Yagoda is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Alan Yagoda has authored 104 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Surgery, 30 papers in Oncology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Alan Yagoda's work include Bladder and Urothelial Cancer Treatments (45 papers), Urinary and Genital Oncology Studies (23 papers) and Renal cell carcinoma treatment (7 papers). Alan Yagoda is often cited by papers focused on Bladder and Urothelial Cancer Treatments (45 papers), Urinary and Genital Oncology Studies (23 papers) and Renal cell carcinoma treatment (7 papers). Alan Yagoda collaborates with scholars based in United States and Russia. Alan Yagoda's co-authors include Howard I. Scher, Willet F. Whitmore, Robin C. Watson, Cora N. Sternberg, Nancy L. Geller, Daniel Petrylak, Pramod C. Sogani, Harry W. Herr, Michael J. Morse and Lora Weiselberg and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Alan Yagoda

103 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium

1988 763 citations Janice Gabrilove, Ann A. Jakubowski et al. New England Journal of Medicine profile →
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

1989 540 citations Cora N. Sternberg, Alan Yagoda et al. Cancer profile →
Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium

1985 513 citations Cora N. Sternberg, Alan Yagoda et al. The Journal of Urology profile →
M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the Urothelium

1988 492 citations Cora N. Sternberg, Alan Yagoda et al. The Journal of Urology profile →

Peers

Countries citing papers authored by Alan Yagoda

Since Specialization

Citations

This map shows the geographic impact of Alan Yagoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Yagoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Yagoda more than expected).

Fields of papers citing papers by Alan Yagoda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Yagoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Yagoda. The network helps show where Alan Yagoda may publish in the future.

Co-authorship network of co-authors of Alan Yagoda

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Yagoda. A scholar is included among the top collaborators of Alan Yagoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Yagoda. Alan Yagoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of prostate cancer growth by estramustine and colchicine 1995 ·The Prostate ·Marwan Fakih, (unknown), (unknown), Kenneth J. Pienta, Alan Yagoda	28
2	Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer 1993 ·Cancer ·Alan Yagoda, Daniel Petrylak	323
3	Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy 1991 ·Cancer ·Nancy L. Geller, (unknown), Darryl Penenberg, Howard I. Scher, Alan Yagoda	113
4	Neo‐adjuvant Chemotherapy for Invasive Bladder Cancer. Experience with the M‐VAC Regimen 1989 ·British Journal of Urology ·Howard I. Scher, H.W. Herr, (unknown), William R. Fair, George J. Bosl, M. Morse, Pramod C. Sogani, (unknown), D. David Dershaw, Victor E. Reuter, Tracy Curley, E. Darracott Vaughan, W.F. Whitmore, Alan Yagoda	85
5	Phase II trial of trimetrexate in patients with advanced renal cell carcinoma 1989 ·European Journal of Cancer and Clinical Oncology ·Cora N. Sternberg, Alan Yagoda, Howard I. Scher, George J. Bosl, D. David Dershaw, (unknown), Collette Houston, Richard J. Rosenbluth, Vincent Vinciguerra, (unknown)	9
6	Chemotherapy in the Management of Bladder Tumours 1989 ·Drugs ·W.F. Whitmore, Alan Yagoda	7
7	Phase I study of granulocyte colony-stimulating factor in patients with transitional cell carcinoma of the urothelium. 1988 ·Journal of Clinical Investigation ·Janice Gabrilove, Ann A. Jakubowski, Katie Fain, John Grous, Howard I. Scher, C. Sternberg, Alan Yagoda, Bayard Clarkson, MA Bonilla, Herbert F. Oettgen	183
8	Chemotherapeutic Management of Invasive Bladder Carcinoma 1988 ·European Urology ·Cora N. Sternberg, Alan Yagoda, Howard I. Scher, Robin C. Watson, Harry W. Herr, (unknown), Pramod C. Sogani, E. Darracott Vaughan, Neil H. Bander, Nancy L. Geller, William R. Fair, Willet F. Whitmore	2
9	A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. 1988 ·Journal of Clinical Oncology ·George J. Bosl, Nancy L. Geller, Dean F. Bajorin, S P Leitner, Alan Yagoda, Robert B. Golbey, Howard I. Scher, N. Vogelzang, James R. Auman, Robert W. Carey	183
10	Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium breakdown → 1988 ·New England Journal of Medicine ·Janice Gabrilove, Ann A. Jakubowski, Howard I. Scher, Cora N. Sternberg, G Wong, John Grous, Alan Yagoda, Katie Fain, M A Moore, Bayard Clarkson, Herbert F. Oettgen, (unknown), Karl Welte, L M Souza	763
11	Experimental Studies on the Response of Nude Mouse-Grown Human Urothelial Cancer to High Dose of 1-β-D-Arabinofuranosylcytosine 1988 ·Cancer Investigation ·Andreas P. Kyriazis, Alan Yagoda, Aikaterini A. Kyriazis, George Royer	5
12	Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors 1987 ·The American Journal of Medicine ·Howard I. Scher, Alan Yagoda	76
13	Vinblastine and Methotrexate for Advanced Bladder Cancer 1985 ·The Journal of Urology ·Tauseef Ahmed, Alan Yagoda, Burton Needles, Howard I. Scher, Robin C. Watson, Nancy L. Geller	26
14	Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors 1985 ·The American Journal of Medicine ·George J. Bosl, Alan Yagoda, Robert B. Golbey, Willet F. Whitmore, Harry W. Herr, Pramod C. Sogani, Michael Morse, Nicholas J. Vogelzang, Gordon R. MacDonald	45
15	Experimental studies on the radiation-modifying effect of cis-diamminedichloroplatinum II (DDP) in human bladder transitional cell carcinomas grown in nude mice 1983 ·Cancer ·Andreas P. Kyriazis, Alan Yagoda, James G. Kereiakes, (unknown), (unknown), Willet F. Whitmore	29
16	Metastatic colorectal carcinoma: A prospective randomized trial of Methyl-CCNU, 5-fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-strep) 1983 ·Cancer ·Nancy E. Kemeny, Alan Yagoda, David Braun	23
17	Theoretical considerations in the treatment of seminoma. 1979 ·PubMed ·Alan Yagoda, Davor Vugrin	8
18	Chemotherapy of malignant hemangiopericytoma 1978 ·Cancer ·Peter Wong, Alan Yagoda	110
19	A clinical study of the natural history of lymphosarcoma and reticulum cell sarcoma 1974 ·European Journal of Cancer (1965) ·(unknown), Alan Yagoda, Burton J. Lee, Irwin H. Krakoff	3
20	Bleomycin, an Antitumor Antibiotic 1972 ·Annals of Internal Medicine ·Alan Yagoda, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	236

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact